Assess whether biosimilarity is analytically justified (b278ab)

Situation

After a site-change that invalidates stability claims, inspection-readiness findings at a CMO is what clinical-development physician can touch in an RWE group proposing a post-marketing study instead of a new RCT. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this CMC and Development Pathways file.

Decision

Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using inspection-readiness findings at a CMO after a site-change that invalidates stability claims.

Hypotheses to test

• The population in inspection-readiness findings at a CMO is the one a site-change that invalidates stability claims named, so Proceed under protocol follows for this CMC and Development Pathways file.
• The population in inspection-readiness findings at a CMO is adjacent only to a site-change that invalidates stability claims; Pause the pathway is the honest Pharma & Life Sciences call.
• An RWE group proposing a post-marketing study instead of a new RCT already contained a site-change that invalidates stability claims before inspection-readiness findings at a CMO arrived; no new CMC and Development Pathways path.
• Provenance on inspection-readiness findings at a CMO after a site-change that invalidates stability claims is broken; do not pick Proceed under protocol or Pause the pathway yet.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in inspection-readiness findings at a CMO after a site-change that invalidates stability claims.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on biosimilarity is analytically justified.
• For this Pharma & Life Sciences CMC and Development Pathways file, read inspection-readiness findings at a CMO against a site-change that invalidates stability claims and write the one fact that would move biosimilarity is analytically justified for clinical-development physician.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (inspection-readiness findings at a CMO after a site-change that invalidates stability claims). Lead with the Pharma & Life Sciences option inspection-readiness findings at a CMO can support after a site-change that invalidates stability claims, then the two facts that force it, then the Monday action for clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT.